Rapamycin is highlighted as a clean drug, contrasting with the "dirty" nature of resveratrol, which has been largely dismissed by pharmaceutical companies. The initial excitement around resveratrol stemmed from a study showing its potential to activate sirtuins and extend lifespan in yeast. Despite the media frenzy ignited by its association with red wine, interest in resveratrol has waned in the aging research community.
